Fig. 6: Maintenance of remission by YE6144 in the NZB/W F1 mouse model of SLE.
From: Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease
a The scheme of YE6144 treatment combined with BZ administration b Autoantibody production. Serum anti-dsDNA IgG levels in NZB/W F1 female mice (31–34 weeks of age at week 0) treated with either DMSO (n = 13) or YE6144 (n = 12) after BZ injection were analyzed by ELISA. The dashed line denotes the mean data from untreated WT C57BL/6 (B6) mice (n = 3). c The LLPC number in the spleen from WT B6 mice (n = 8) and NZB/W F1 mice in b at 10 weeks after the initial YE6144 injection (age 41–44 weeks) was analyzed by flow cytometry. d Spleen weight of mice in c. e The proteinuria score of WT B6 mice (n = 10) and NZB/W F1 mice in c. f, g Kidney pathology of mice in c analyzed as in Fig. 2d, e. Representative images are shown and scale bars correspond to 20 μm (f). h ISG expression. The Ifit1 mRNA level in peripheral blood from WT B6 mice (n = 5) and NZB/W F1 mice in c was analyzed by RT-qPCR. Data were compiled from three independent experiments. Horizontal bars represent mean ± SEM (b–d, g, h) or median (e). **P < 0.01, ***P < 0.001 (two-sided paired t test in b [the same treatment samples]; two-sided Student’s t test in b [different treatment samples], c, d, g, h; and two-sided Mann–Whitney U test in e).
